UK-based contract research organisation QED Clinical Services has established operations in India to extend its clinical research reach across the Asia Pacific region.
The CRO's new Ahmedabad-based subsidiary will be led by Ali Sajjad Bohra, who previously served as Asia Pacific regional director for the clinical monitoring group of a large global CRO.
Bohra said: “India and Asia Pacific will continue to have focus and will remain key markets for the drug development activities for biopharmaceutical companies on account of a variety of benefits.
“With our in-depth experience and knowledge of the region, we are committed to provide customised, cost-efficient and high quality services to both global as well as local clients.”
QED Clinical Services India will conduct trials in India and act as a hub for QED's Asia Pacific operations to enhance working arrangements with its local partners across the region.
QED's CEO Thomas Ogorka said: “The creation of QED Clinical Services India means that we can better meet the global development needs of our sponsors by giving access to vast patient populations via regional experts on the ground.
“India continues to receive great focus as an emerging territory and QED's presence here means we can leverage its high-quality capabilities.”
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...